First Pacific Financial Trims Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

First Pacific Financial reduced its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,130 shares of the medical research company’s stock after selling 19 shares during the period. First Pacific Financial’s holdings in Thermo Fisher Scientific were worth $1,131,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Thermo Fisher Scientific by 0.6% in the third quarter. Vanguard Group Inc. now owns 32,760,738 shares of the medical research company’s stock worth $16,582,503,000 after acquiring an additional 180,618 shares in the last quarter. State Street Corp boosted its stake in Thermo Fisher Scientific by 0.3% in the 2nd quarter. State Street Corp now owns 16,116,956 shares of the medical research company’s stock worth $8,414,693,000 after purchasing an additional 55,458 shares in the last quarter. Morgan Stanley lifted its stake in shares of Thermo Fisher Scientific by 0.4% in the third quarter. Morgan Stanley now owns 12,418,429 shares of the medical research company’s stock worth $6,285,838,000 after buying an additional 50,736 shares in the last quarter. Moneta Group Investment Advisors LLC increased its position in shares of Thermo Fisher Scientific by 104,536.8% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 8,355,245 shares of the medical research company’s stock valued at $4,601,150,000 after acquiring an additional 8,347,260 shares in the last quarter. Finally, Providence Capital Advisors LLC lifted its position in Thermo Fisher Scientific by 61,754.7% in the 1st quarter. Providence Capital Advisors LLC now owns 5,842,175 shares of the medical research company’s stock valued at $10,136,000 after acquiring an additional 5,832,730 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the transaction, the senior vice president now owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The disclosure for this sale can be found here. Insiders have sold a total of 50,277 shares of company stock worth $28,513,384 over the last quarter. Company insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Trading Up 1.9 %

TMO stock opened at $579.37 on Thursday. The firm has a market cap of $220.92 billion, a PE ratio of 37.50, a price-to-earnings-growth ratio of 2.39 and a beta of 0.80. The firm has a fifty day moving average price of $564.32 and a 200 day moving average price of $519.80. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.39 and a current ratio of 1.75. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.64 by $0.03. The business had revenue of $10.89 billion during the quarter, compared to analyst estimates of $10.73 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The company’s revenue for the quarter was down 4.9% on a year-over-year basis. During the same period last year, the company earned $5.40 EPS. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 15th. Investors of record on Friday, March 15th will be issued a dividend of $0.39 per share. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s payout ratio is presently 10.10%.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. TheStreet raised Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a research report on Friday, December 22nd. Wolfe Research initiated coverage on shares of Thermo Fisher Scientific in a report on Wednesday, December 13th. They issued an “outperform” rating and a $575.00 target price on the stock. Royal Bank of Canada raised their price target on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. Raymond James increased their target price on Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. Finally, HSBC initiated coverage on shares of Thermo Fisher Scientific in a research report on Monday, December 18th. They set a “buy” rating and a $610.00 target price for the company. Five analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus target price of $599.00.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.